BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 27184342)

  • 1. Number of metastatic lymph nodes as determinant of outcome after salvage radical prostatectomy for radiation-recurrent prostate cancer.
    Gugliemetti G; Sukhu R; Conca Baenas MA; Meeks J; Sjoberg DD; Eastham JA; Scardino PT; Touijer K
    Actas Urol Esp; 2016 Sep; 40(7):434-9. PubMed ID: 27184342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
    Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
    Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease.
    Badani KK; Reddy BN; Moskowitz EJ; Paulucci DJ; Beksac AT; Martini A; Whalen MJ; Skarecky DW; Huynh LM; Ahlering TE
    Urol Oncol; 2018 Jun; 36(6):310.e1-310.e6. PubMed ID: 29625782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.
    Chade DC; Shariat SF; Cronin AM; Savage CJ; Karnes RJ; Blute ML; Briganti A; Montorsi F; van der Poel HG; Van Poppel H; Joniau S; Godoy G; Hurtado-Coll A; Gleave ME; Dall'Oglio M; Srougi M; Scardino PT; Eastham JA
    Eur Urol; 2011 Aug; 60(2):205-10. PubMed ID: 21420229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.
    Kim DK; Koo KC; Abdel Raheem A; Kim KH; Chung BH; Choi YD; Rha KH
    PLoS One; 2016; 11(3):e0152391. PubMed ID: 27031340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy.
    Meijer HJ; van Lin EN; Debats OA; Witjes JA; Span PN; Kaanders JH; Barentsz JO
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1405-10. PubMed ID: 21640507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer.
    Carlsson SV; Tafe LJ; Chade DC; Sjoberg DD; Passoni N; Shariat SF; Eastham J; Scardino PT; Fine SW; Touijer KA
    J Urol; 2013 Apr; 189(4):1314-8. PubMed ID: 23085057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy.
    Eisenberg MS; Karnes RJ; Kaushik D; Rangel L; Bergstralh EJ; Boorjian SA
    J Urol; 2013 Nov; 190(5):1735-41. PubMed ID: 23727312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
    JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up.
    Winter A; Henke RP; Wawroschek F
    BMC Urol; 2015 Feb; 15(1):10. PubMed ID: 25881245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria.
    Mandel P; Steuber T; Ahyai S; Kriegmair M; Schiffmann J; Boehm K; Heinzer H; Michl U; Schlomm T; Haese A; Huland H; Graefen M; Tilki D
    BJU Int; 2016 Jan; 117(1):55-61. PubMed ID: 25711672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of prostate carcinoma death in patients with lymph node metastasis.
    Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG
    Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases.
    Wenger H; Weiner AB; Razmaria A; Paner GP; Eggener SE
    Urol Oncol; 2017 Jan; 35(1):31.e1-31.e6. PubMed ID: 27692833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in lymph node-positive prostate cancer.
    Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
    Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.